Idioma:

Cognitive remission: a novel objective for the treatment of major depression?

Bortolato, Beatrice ; Miskowiak, Kamilla W ; Köhler, Cristiano A ; Maes, Michael ; Fernandes, Brisa S ; Berk, Michael ; Carvalho, André F

BMC medicine, 2016-01, Vol.14 (9), p.9-9, Article 9 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Cognitive remission: a novel objective for the treatment of major depression?
Autor: Bortolato, Beatrice ; Miskowiak, Kamilla W ; Köhler, Cristiano A ; Maes, Michael ; Fernandes, Brisa S ; Berk, Michael ; Carvalho, André F
Assuntos: Adult ; Antidepressive Agents - therapeutic use ; Attention - drug effects ; Care and treatment ; Cognition - drug effects ; Cognition disorders ; Cognition Disorders - drug therapy ; Cognition Disorders - etiology ; Complications and side effects ; Depressive Disorder, Major - complications ; Depressive Disorder, Major - drug therapy ; Depressive Disorder, Major - psychology ; Humans ; Major depressive disorder ; Memory - drug effects ; Meta-Analysis as Topic ; Nootropic Agents - therapeutic use ; Opinion ; Patient outcomes ; Prevention ; Recovery of Function ; Remission Induction ; Risk factors
É parte de: BMC medicine, 2016-01, Vol.14 (9), p.9-9, Article 9
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Cognitive dysfunction in major depressive disorder (MDD) encompasses several domains, including but not limited to executive function, verbal memory, and attention. Furthermore, cognitive dysfunction is a frequent residual manifestation in depression and may persist during the remitted phase. Cognitive deficits may also impede functional recovery, including workforce performance, in patients with MDD. The overarching aims of this opinion article are to critically evaluate the effects of available antidepressants as well as novel therapeutic targets on neurocognitive dysfunction in MDD. Conventional antidepressant drugs mitigate cognitive dysfunction in some people with MDD. However, a significant proportion of MDD patients continue to experience significant cognitive impairment. Two multicenter randomized controlled trials (RCTs) reported that vortioxetine, a multimodal antidepressant, has significant precognitive effects in MDD unrelated to mood improvement. Lisdexamfetamine dimesylate was shown to alleviate executive dysfunction in an RCT of adults after full or partial remission of MDD. Preliminary evidence also indicates that erythropoietin may alleviate cognitive dysfunction in MDD. Several other novel agents may be repurposed as cognitive enhancers for MDD treatment, including minocycline, insulin, antidiabetic agents, angiotensin-converting enzyme inhibitors, S-adenosyl methionine, acetyl-L-carnitine, alpha lipoic acid, omega-3 fatty acids, melatonin, modafinil, galantamine, scopolamine, N-acetylcysteine, curcumin, statins, and coenzyme Q10. The management of cognitive dysfunction remains an unmet need in the treatment of MDD. However, it is hoped that the development of novel therapeutic targets will contribute to 'cognitive remission', which may aid functional recovery in MDD.
Editor: England: BioMed Central Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Cognitive remission: a novel objective for the treatment of major depression?

Bortolato, Beatrice ; Miskowiak, Kamilla W ; Köhler, Cristiano A ; Maes, Michael ; Fernandes, Brisa S ; Berk, Michael ; Carvalho, André F

England: BioMed Central Ltd

Buscando em bases de dados remotas. Favor aguardar.